IL316017A - Combined treatment for cancer - Google Patents

Combined treatment for cancer

Info

Publication number
IL316017A
IL316017A IL316017A IL31601724A IL316017A IL 316017 A IL316017 A IL 316017A IL 316017 A IL316017 A IL 316017A IL 31601724 A IL31601724 A IL 31601724A IL 316017 A IL316017 A IL 316017A
Authority
IL
Israel
Prior art keywords
combination therapy
treating cancer
cancer
treating
therapy
Prior art date
Application number
IL316017A
Other languages
English (en)
Hebrew (he)
Inventor
Sabina Chiara Cosulich
Mark R Albertella
Jessica S Brown
Elisabetta Leo
Original Assignee
Astrazeneca Ab
Sabina Chiara Cosulich
Mark R Albertella
Jessica S Brown
Elisabetta Leo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Sabina Chiara Cosulich, Mark R Albertella, Jessica S Brown, Elisabetta Leo filed Critical Astrazeneca Ab
Publication of IL316017A publication Critical patent/IL316017A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL316017A 2022-04-07 2023-04-06 Combined treatment for cancer IL316017A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362613P 2022-04-07 2022-04-07
PCT/EP2023/059130 WO2023194530A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
IL316017A true IL316017A (en) 2024-11-01

Family

ID=86226547

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316017A IL316017A (en) 2022-04-07 2023-04-06 Combined treatment for cancer

Country Status (11)

Country Link
US (1) US20250213556A1 (https=)
EP (1) EP4504182A1 (https=)
JP (1) JP2025511402A (https=)
KR (1) KR20240170957A (https=)
CN (1) CN119212702A (https=)
AU (1) AU2023250031A1 (https=)
CA (1) CA3254949A1 (https=)
IL (1) IL316017A (https=)
MX (1) MX2024012392A (https=)
TW (1) TW202404661A (https=)
WO (1) WO2023194530A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600137A (zh) * 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.

Also Published As

Publication number Publication date
JP2025511402A (ja) 2025-04-15
KR20240170957A (ko) 2024-12-05
CA3254949A1 (en) 2023-10-12
EP4504182A1 (en) 2025-02-12
CN119212702A (zh) 2024-12-27
TW202404661A (zh) 2024-02-01
WO2023194530A1 (en) 2023-10-12
US20250213556A1 (en) 2025-07-03
AU2023250031A1 (en) 2024-11-14
MX2024012392A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
IL304275A (en) Cancer treatment methods
PT4225297T (pt) Terapia de combinação para o tratamento de cancro
IL307964A (en) Combined treatment for cancer
IL320332A (en) Cancer treatment methods
ZA202310076B (en) Combination therapies for treating cancer
IL319513A (en) Compounds for cancer treatment
IL316016A (en) Combined treatment for cancer
IL316017A (en) Combined treatment for cancer
GB202301902D0 (en) Combination therapy for cancer
IL288178A (en) Combined gmci and ddri treatment for cancer
GB202218395D0 (en) Cancer therapy
IL317573A (en) Combination therapy for cancer treatment
IL316019A (en) Combined treatment for cancer
IL305777A (en) Medical combination for cancer treatment
IL326216A (en) Combination therapy for prostate cancer
CA3272243A1 (en) Combination therapy for treating cancer
HK40121856A (en) Combination therapy for treating cancer
HK40121918A (en) Combination therapy for treating cancer
GB202208893D0 (en) Combination therapy for cancer
IL317472A (en) Arbecycline for cancer treatment
HK40107047A (en) Therapeutic combination for treating cancer
IL320482A (en) Combination therapy for cancer treatment
GB202508616D0 (en) Combination therapy for cancer
CA3302004A1 (en) Combination therapy for treating prostate cancer
CA3307092A1 (en) Combination therapy for cancer treatment